Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

DPIs CONSIDERED MEDICALLY ACCEPTABLE ALTERNATIVE TO CFC PRODUCTS, FDA ADVISORY CMTE. SAYS; POTENCIES OF CFC-FREE AND CFC PRODUCTS SHOULD BE COMPARED

Executive Summary

Dry powder inhalers are a technically and medically feasible alternative to CFC-containing metered dose inhalers, FDA's Pulmonary-Allergy Drugs Advisory Committee concluded at its April 11 meeting. "What we are hearing...is that people feel that there is a role for DPIs, and with most patients they could be a substitute," summarized Committee Chairperson Shirley Murphy, MD, University of New Mexico.

You may also be interested in...



FDA Pediatric Drug Division Director Will Be GSK’s Shirley Murphy

Former GlaxoSmithKline NeuroHealth Specialty Division VP Shirley Murphy, MD, will become the first director of FDA's Division of Pediatric Drug Development effective Sept. 9

FDA Pediatric Drug Division Director Will Be GSK’s Shirley Murphy

Former GlaxoSmithKline NeuroHealth Specialty Division VP Shirley Murphy, MD, will become the first director of FDA's Division of Pediatric Drug Development effective Sept. 9

CFC-Containing MDIs Are "Essential" Until Multiple Alternatives Available

More than one CFC-free product alternative must be available before FDA phases out a CFC-containing metered dose inhaler that is available under multiple NDAs or in multiple strengths, the agency suggests in a proposed rule on ozone depleting substances (ODS) published in the Sept. 1 Federal Register.

UsernamePublicRestriction

Register

PS045148

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel